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Abstract Human Papillomavirus (HPV) is the main cause of
cervical cancer and its precursor lesions. Transformation may
be induced by several mechanisms, including oncogene acti-
vation and genome instability. Individual differences in DNA
damage recognition and repair have been hypothesized to
influence cervical cancer risk. The aim of this study was to
evaluate whether the double strand break gene polymor-
phisms XRCC2 R188H G>A (rs3218536), XRCC3 T241M
C>T (rs861539) and R243H G>A (rs77381814) are associat-
ed to cervical cancer in Argentine women. A case control
study consisting of 322 samples (205 cases and 117 controls)
was carried out. HPV DNA detection was performed by PCR
and genotyping of positive samples by EIA (enzyme immu-
noassay). XRCC2 and 3 polymorphisms were determined by
pyrosequencing. The HPV-adjusted odds ratio (OR) of
XRCC2 188 GG/AG genotypes was OR=2.4 (CI=1.1–4.9,
p=0.02) for cervical cancer. In contrast, there was no in-
creased risk for cervical cancer with XRCC3 241 TT/CC
genotypes (OR=0.48; CI=0.2–1; p=0.1) or XRCC3
241 CT/CC (OR=0.87; CI=0.52–1.4; p=0.6). Regarding
XRCC3 R243H, the G allele was almost fixed in the
population studied. In conclusion, although the sample
size was modest, the present data indicate a statistical
association between cervical cancer and XRCC2 R188H
polymorphism. Future studies are needed to confirm
these findings.
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Introduction
It is wildly accepted that infection with Human Papillomavi-
rus (HPV) is the leading cause of cervical cancer. However,
HPV infection is very common and in most women it clears
up naturally in about 8–12 months. It is estimated that less
than 1 % of HPV positive women will progress to severe
dysplasia or cervical cancer [1]. The combination of factors
that predispose to neoplasia in infected tissue is poorly under-
stood. Much effort has been given to HPVand environmental
factors, but the role of host susceptibility to cervical carcino-
genesis remains largely unknown.
Studies performed on biological and adoptive sisters of
cancer patients identified that development of cervical can-
cer depends, to a significant extent, on inherited genetic
factors [2]. Among these, variants of DNA repair genes
are frequently correlated with a higher risk of several human
solid tumors. We [3] and others [4–6] have explored poly-
morphisms in excision nucleotide genes that could be in-
volved in cervical cancer susceptibility. Here, we expand
our evaluation to DNA double strand break (DBS) repair
polymorphisms in XRCC3 and XRCC2 genes. These genes
share essential roles in homologous recombination (HR), a
key repair pathway by which somatic cells maintain genome
integrity following DNA replication [7].
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Previous studies have shown that genomic instability is a
crucial event in HPV associated cancers, with a significant
increase in single and double strand breaks [8, 9]. Experimen-
tal data also suggest that chromosomal aberrations may be the
result of viral onco-proteins action [10, 11]. In this sense,
introduction of HPV E6 and E7 proteins in keratinocytes
increased the number of cells with phosphorylated histone
H2AX, a marker of DSB damage [12]. Current analyses show
that replication of integrated HPV may induce local
rearrangements within the integration locus, activating DNA
damage checkpoints and recruiting HR proteins [13, 14].
These findings led us to speculate that polymorphisms in
HR genes may be directly involved in cervical cancer risk.
Some of the XRCC2 and XRCC3 single nucleotide poly-
morphisms (SNPs) have been related to human cancers. A G-
A substitution at codon 188 of XRCC2, which changes Arg
for His (c.563 G>A; rs3218536), may carry a small but
significant risk to colorectal [15] and breast cancer [16–18].
While these associations need to be evaluated in larger studies,
the substitution is located in a conservative amino acid that
does not belong to any known functional motive [16]. Another
relevant variant is XRCC3 T241M (exon 7, c.722C>T,
rs861539), which several authors have associated with breast
cancer [15, 18]. In support of this line, mammalian cells
transfected with XRCC3 241M led to a slightly but signifi-
cance resistance to DSB inducers in relation to the wild type
[19]. However, the association between rs861539 and cervical
cancer is inconclusive [6, 20–22].
Material and Methods
A total of 322 cervical samples were collected from women
attending public hospitals that were part of an anonymous
specimen data bank in La Plata, Argentina. Samples
corresponded to 205 normal cytologies and 117 squamous
cervical cancers. Cervical exfoliated cells from the ecto-
endocervix were collected using a cytobrush or spatula. Sam-
ples were eluted in 5 ml of phosphate-buffered saline (PBS),
pelleted, and kept frozen at −80 °C. Biopsy specimens were
fixed in formalin and paraffin-embedded and kept at room
temperature.
DNA Extraction
Paraffin-embedded samples were washed twice with xylol and
finally with 100 % ethanol, re-suspended in 350 ml of pro-
teinase K digestion buffer (250 mg/ml), and incubated for 2 h
at 56 °C. Cervical exfoliated cell pellets and frozen biopsies
were suspended and washed twice with 1 ml of PBS, and
incubated for 24 h at 56 °C in 400 ml of digestion (extraction)
buffer (50 mM Tris-ClH pH 8,5; 1 mM EDTA; 1 % Triton
3100 and 0,5 % Tween 20) containing 250 mg/ml of protein-
ase K (Promega). After proteinase digestion, samples were
boiled for 10 min at 100 °C. DNA purification was conducted
by the Salting out (direct protein precipitation methodology)
procedure [23]. Finally, the DNAwas (re)suspended in distil-
late water and stored at −20 °C.
HPV Genotyping
HPV DNAwas detected by nested PCR using two rounds of
amplification, yielding a 150 bp PCR amplicon that includes a
conserved sequence of the viral genome. The primers for first
round were MY09/11 [24], and for the second round GP
05/06+ [25]. GP06 primers were biotinylated for later PCR
enzyme immune assay [26]. Protocol and cycling conditions
for DNA amplification were described elsewhere [3]. PCR
products were electrophoresed in 2 % agarose gels, stained
with SaferGreen™ (Invitrogen) and visualized in blue light by
SafeImager™ (Invitrogen).
PCR EIA
Briefly, 5 uL of the positive amplicons was captured on
streptavidin-coated Maxi Sorp wells (Nunc, Thermo Fisher
Scientific, Rochester, NY). The biotin labeled Gp was dena-
tured with 0.2N Na(OH) at room temperature for 30′, washed
three times (0.25× standard saline citrate, 20% Tween 20) and
hybridized with fluorescein-labeled oligoprobes correspond-
ing to HPV types: 6, −11, −16, −18, −31, −33, −35, −39, −45,
−51, −52, −56, −58, and −66. The plate was incubated for
20 min at 60 °C with 5 pmol of each probe per 100 uL
hybridization buffer (5× standard saline citrate, 20 % Tween
20). After a washing step, samples were incubated for 30 min
with anti-fluorescein monoclonal antibodies (1:1000)
(Millipore, Billerica, MA). After two additional washing
steps, the reaction was revealed with 1-Step Turbo TMB-
ELISA (Pierce Biotechnology, Rockford, IL). Coloring was
stopped after 10 min by 1 M sulfuric acid and the optical
density of the color reaction was measured by spectrophotom-
etry (BioRad) at 405 nm.
Amplification and Pyrosequencing of XRCC2 R188H
(rs3218536) and XRCC3 T241M (rs861539), R243H
(rs77381814) Polymorphisms
The XRCC2 and XRCC3 primers were designed with
FastPCR software (Primer Digital ltd, Finland) version
6.1.55. The XRCC2 R188H primers delimited a region of
151 bp (forward, XRCC227370-90 5′-CTG GATAGA CCG
CGT CAATGG-3′; reverse, BioX2-27501-21, biotin-5′-ATG
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AGC TCG AGG CTT TCT GCA-3′). Each PCR mix
contained 0.5 uM of forward and reverse primers; 2 mM of
each dNTP; 2 mM Cl2Mg; 1× PCR buffer (ClK 500 mM;
Tris.ClH 100 mM; pH 9.0; Triton 100 1 %), 1 unit of Taq
DNA polymerase (Inbio, Argentina) and 5 uL of DNA sample
in a total volume of 50 uL. Cycling program was carried out
with an initial denaturing step of 92 °C for 3 min, followed by
35 cycles of 30 s at 92 °C, 30 s at 60 °C, and 45 s at 72 °C, with
a final elongation step of 72 °C for 5 min.
The XRCC3 primers delimited a region of 152 bp (for-
ward, XRCC31742-62, 5′-CTC ACC TGG TTG ATG CAC
AGC-3′; reverse, X3-241-Piro, biotin-5′-TGG TCA TCG
ACT CGG TGG CAG-3′). An additional XRCC3 polymor-
phism, R243H (rs77381814), was also genotyped due to
proximity to T241M (rs861539). Each PCR mix contained
0.5 uM of forward and reverse primers; 2 mM of each dNTP;
1 mM Cl2Mg; 1× PCR buffer (ClK 500 mM; Tris.ClH
100 mM; pH 9.0; Triton 100 1 %), 1 unit of Taq DNA
polymerase (Inbio, Argentina), 5 uL of DNA sample in a total
volume of 50 uL. Cycling program was carried out with an
initial denaturing step of 92 °C for 3 min, followed by 35 cy-
cles of 30 s at 92 °C, 50 s at 59 °C, and 45 s at 72 °C, with a
final elongation step of 72 °C for 5 min.
The obtained PCR products were electrophoresed in aga-
rose gel (2 %), stained with SaferGreen and visualized in blue
light by SafeImager (Invitrogen). Twenty five micro-liters of
each positive PCR product was transferred to 96-wells
microplate and sequenced by Pyrosequencing PSQ96 HS
System (Biotage, Uppsala, Sweden) according to manufac-
turers’ instructions. The sequencing primer for XRCC2 was:
XR2-188-Int, 5′-TTG TAAATGACTATC-3′, and nucleotide
dispensation order was: TAGACTGTC. The internal primer
for XRCC3 was XR3-241-Int, 5′-GGC ACT GCT CAG
CTC-3′ and could detect both XRCC3 T241M (rs861539)
Fig. 1 Experimental pyrogram patterns for analysis of: a XRCC2 188 AA; b XRCC2 188 GG; c XRCC3 241 TT and 243 GG; d XRCC3 241 CC
and 243 GA; e XRCC3 241 TC and 243 GG (Note that XRCC3 sequence in pyrograms is complementary to consensus)
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and R243H (rs77381814) SNPs. The nucleotide dispensation
order for this reaction was: GACTAGCAGCGA. Representa-
tive pyrograms for XRCC2 and XRCC3 SNPs are shown in
Fig. 1.
Statistical Analysis
Statistical associations were assessed by the chi-square test,
p values were two sided, and significance was set at p<0.05.
For risk estimation, odds ratios and 95 % confidence inter-
val were obtained by binary logistic regression using the
SPSS software (SPSS Inc).
Results
Overall HPV DNAwas detected in 39 % (80/205) of controls
and 67 % (78/117) of cases. According to our methodology,
the distribution of HPV types among the positive samples
showed that 29 % of detection in controls and 50 % in case
subjects belonged to high-risk types. HPV 16 was the preva-
lent type in control subjects (55 %), followed by HPV 18
(18.9 %), HPV 11 (9.4 %), HPV 6 (5.4 %), HPV 31 (4 %) and
HPV 33 (1.3 %) Similar results were obtained for case pa-
tients: HPV 16 was the prevalent type (65.7 %), followed by
HPV18 (10 %), HPV 31 (5.7 %), HPV 33 (4.2 %), HPV 11
(2.8%) and HPV 45 (1.4%). Co-infection frequency was low;
among HPV positive samples 15.6 % of controls and 7.8 % of
cases had more than one infection.
The allele and genotypes frequencies of XRCC2 R188H
(rs3218536) and XRCC3 T241M (rs861539) polymor-
phisms are shown in Table 1. All genotype distributions of
controls were consistent with the Hardy Weinberg equilib-
rium (p=0.16 for rs3218536 and p=0.4 for rs861539). For
the additional XRCC3 243 polymorphism (rs77381814), the
GG genotype was almost fixed in the population, with the
exception of one control GA. Figure 1 depicts the obtained
pyrograms for the resulting genotypes. The comparison
between XRCC genotypes and HPV types revealed no
association between infection and polymorphism (Table 2).
Viral types were divided in low and high risk groups in
order to provide sufficient statistical power.
Binary logistic regression was used to calculate odds
ratios for cervical cancer risk. The allele frequency of
XRCC2 188 G (rs3218536) was slightly higher in cases
(0.95) than controls (0.91), but the difference was statisti-
cally significant (p=0.023). In this sense, the homozygous
188 GG genotype was associated with an increasing risk for
cervical cancer (OR=2.3; CI=1.1–4.7; p=0.019) when
compared with XRCC2 188 AG. It is noteworthy that we
did not find any individual carrying the XRCC2 188 AA
genotype. On the other hand, the distribution of XRCC3 241
(rs861539) genotypes remained similar between cases and
controls. In this sense, the allele frequency of XRCC3241 C
was similar in controls (0.61) and cases (0.66).
Table 1 Genotype distribution
of XRCC2 R188H and XRCC3
T241M variants in cases and
controls
aHPV-adjusted odds ratio
Cases Controls Odds ratio
(IC95%)(P)
Odds ratioa
(IC95%) (P)
XRCC2 R188H GG 106 165 2.3 (1.1–4.7) (0.019) 2.4 (1.1–4.9) (0.02)
AG 11 40 Reference Reference
XRCC3 T241M TT 11 32 0.53 (0.24–1.16) (0.11) 0.48 (0.2–1) (0.1)
CT 56 95 0.92 (0.56–1.49) (0.73) 0.87 (0.52–1.4) (0.6)
CC 50 78 Reference Reference
Table 2 Distribution of XRCC genotypes among women infected with low-risk and high-risk HPV types
HPV XRCC2 R188H XRCC3 T241M
Controls P value Cases P value Controls P value Cases P value
AG GG AG GG CC CT TT CC CT TT
Neg 25 100 2 37 51 59 15 17 16 6
Low-riska 4 18 0.8 NS 2 18 0.9 NS 6 9 7 0.9 NS 12 8 0 0.77 NS
High-riskb 11 47 0.8 NS 7 51 0.4 NS 21 27 10 0.9NS 21 32 5 0.43 NS
NS Non significant
a HPV 6, 11, 42
b HPV 16, 18, 31, 33, 45
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Discussion
The role of DNA repair genes on the risk of human cancers
is being increasingly recognized. Genetic instability is a
common feature of human tumors and recent evidence sug-
gests that mutations in DNA repair genes are implicated in
both initiation and cancer progression. Whereas mutations
in high penetrance genes such as the breast cancer genes
BRCA1 and 2 are less frequent, there are low penetrance
polymorphisms that may explain the remaining risk. In this
sense, single nucleotide polymorphisms of DNA repair
genes are extensively studied in breast and ovarian cancer.
Here, we present evidence that supports that XRCC2
R188H (rs3218536) polymorphism may be associated with
cervical cancer.
The frequency of the XRCC2 188 A allele found in this
study was lower than those reported from Europe [16, 27]
and the US [28]. To the best of our knowledge, this is the
first study examining the XRCC2 188 G>A variant in cer-
vical cancer. A meta-analysis performed by Vineis et al. [8]
with data collected from 1985 to 2007 showed that XRCC2
188 A confers a slightly but significantly risk for colorectal
cancer. Other authors have associated XRCC2 Awith breast
and ovarian cancer, but the association remains controver-
sial [16, 27, 29, 30]. Contrary to most cancers studied so far,
we found that the risk allele associated with cervical cancer
was G, not A. Although there is needed more studies to
assess this relation, an intriguing issue is raised as to wheth-
er XRCC2 188 G>A has a different role in cervical cancer,
probably by identifying HPV induced DNA damage in host
genome or by playing a part in viral integration [22].
Despite speculations, few active sites have been demon-
strated for the XRCC2 gene and codon 188 (rs3218536)
does not lie within any of them. Rafii et al. [16] have shown
that XRCC2 is able to form complexes with certain RAD51
paralogs, therefore functional motives remain to be identi-
fied. It is also possible that cancer association is not directly
linked to codon 188, but to another SNP located inside the
Walker motive (ATPase). Similar to this, XRCC3 T241M
(rs861539) polymorphism modifies an aminoacid that does
not lie in a known functional motive, but unlike XRCC2
188 (rs3218536), it has stronger evidence of differential
activity between alleles. In this sense, it was shown that
this variant responds differentially to certain DSB in-
ducers in CHO cells which were transfected with human
variants of XRCC3 [19].
Population studies have shown that the XRCC3 T241M
(rs861539) polymorphism was associated with breast cancer
[15, 18], although the conferred risk, as other low pene-
trance genes confers, is relatively low. We failed at finding a
significant association between rs861539 and cervical can-
cer. These results are in agreement with those found by
others [20–22]. In agreement, a large case control study
performed in Costa Rica, which analyzed the contribution
of DNA repair gene polymorphisms and cervical cancer, did
not identify an association between rs861539 and neoplasia.
It is noteworthy, however, that in that study HPV persistence
was linked to another DNA repair gene variant, XRCC1
codon 399 polymorphism (rs25487) [6].
Despite controversial findings, the link between cervical
cancer risk and genetic variants of DNA repair genes re-
mains to be proved. Our results support the view that func-
tional polymorphisms may influence cervical cancer risk.
Although the mechanism is unknown, recent data suggest
that expression of homologous recombination proteins is
actively involved in HPV induced instability. Kazara et al.
(2009) demonstrated that chromosomal rearrangements
could be triggered by the unscheduled replication of inte-
grated HPV, yielding numerous double strand breaks and
exceeding the cellular DNA repair system [12].
In conclusion, our results provide evidence for a statistical
association between a genetic polymorphism of XRCC2 and
cervical cancer, suggesting that this protein may be specifical-
ly involved in repair of HPV related DNA damage. However,
larger studies are needed to confirm this hypothesis.
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